AN2 Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by AN2 Therapeutics, Inc. on June 3, 2026. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Global Select Market under the symbol ANTX. The record date for the meeting was April 15, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders representing 63.18% of outstanding shares (22,741,535 shares) attended the meeting, establishing a quorum. Two proposals were voted upon:
- Proposal 1: Election of Class I Directors. The following nominees were elected to serve until the 2029 annual meeting:
- Kabeer Aziz: 13,547,536 votes For; 3,958,874 votes Withheld.
- Gilbert Lynn Marks, M.D.: 15,947,854 votes For; 1,558,556 votes Withheld.
- Rob Readnour, Ph.D.: 15,920,563 votes For; 1,585,847 votes Withheld.
- Proposal 2: Ratification of Independent Auditor. The appointment of PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2026, was ratified with 22,724,674 votes For, 13 votes Against, and 16,848 Abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document serves solely to disclose the certified results of the stockholder vote.
Investor Verification Checklist
- Verify the definitive proxy statement (Schedule 14A) filed on April 22, 2026, for detailed biographies of the elected directors and the rationale for the auditor appointment.
- Confirm the total number of shares outstanding as of the record date (35,995,545) against subsequent capitalization tables.
- Review the Company's upcoming 10-K or 10-Q filings for the financial metrics absent from this 8-K.